Farioli Andrea, Ottone Marta, Morganti Alessio G, Compagnone Gaetano, Romani Fabrizio, Cammelli Silvia, Mattioli Stefano, Violante Francesco S
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Deptartments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy.
Cancer Med. 2016 May;5(5):950-9. doi: 10.1002/cam4.656. Epub 2016 Feb 10.
We investigated the association between external beam radiotherapy (EBRT) and pleural and peritoneal mesothelioma among long-term (>5 years) solid cancer survivors. We analyzed data from the US Surveillance, Epidemiology, and End Results (SEER) program (1973-2012). We fitted survival models adjusted by age, gender, race, year, surgery, and relative risk of primary mesothelioma in the county of residence (proxy for individual asbestos exposure). We estimated hazard ratios [HR] with reference to nonirradiated patients. We distinguished between scattered and direct irradiation to study the dose-response. We observed 301 mesotheliomas (265 pleural; 32 peritoneal; 4 others) among 935,637 patients. EBRT increased the risk of mesothelioma (any site; HR 1.34, 95% CI 1.04-1.77). We observed an increased risk of pleural mesothelioma (HR for EBRT 1.34, 95% CI 1.01-1.77), but we did not find signs of a dose-response relationship (HR for scattered irradiation 1.38; HR for direct irradiation 1.23). On the opposite, only direct peritoneal irradiation was associated with peritoneal mesothelioma (HR 2.20, 95% CI 0.99-4.88), particularly for latencies ≥10 years (HR 3.28, 95% CI 1.14-9.43). A competing risks analysis revealed that the clinical impact of radiation-induced mesothelioma was limited by the high frequency of competing events. The cumulative incidence function of mesothelioma after 40 years of observation was very low (nonirradiated patients 0.00032, irradiated patients 0.00055).EBRT might be a determinant of mesothelioma. Longer latency periods are associated with higher risks, while the dose-response seems nonlinear. The clinical impact of mesothelioma after EBRT for primary solid cancers is limited.
我们调查了长期(>5年)实体癌幸存者中体外放射治疗(EBRT)与胸膜和腹膜间皮瘤之间的关联。我们分析了美国监测、流行病学和最终结果(SEER)计划(1973 - 2012年)的数据。我们拟合了根据年龄、性别、种族、年份、手术以及居住县原发性间皮瘤的相对风险(个体石棉暴露的代理指标)进行调整的生存模型。我们以未接受照射的患者为参照估计风险比[HR]。我们区分了散在照射和直接照射以研究剂量反应关系。在935,637名患者中,我们观察到301例间皮瘤(265例胸膜间皮瘤;32例腹膜间皮瘤;4例其他类型)。EBRT增加了间皮瘤(任何部位)的风险(HR 1.34,95% CI 1.04 - 1.77)。我们观察到胸膜间皮瘤风险增加(EBRT的HR为1.34,95% CI 1.01 - 1.77),但未发现剂量反应关系的迹象(散在照射的HR为1.38;直接照射的HR为1.23)。相反,仅直接腹膜照射与腹膜间皮瘤相关(HR 2.20,95% CI 0.99 - 4.88),特别是潜伏期≥10年时(HR 3.28,95% CI 1.14 - 9.43)。一项竞争风险分析显示,辐射诱发的间皮瘤的临床影响受到竞争事件高发生率的限制。观察40年后间皮瘤的累积发病率函数非常低(未接受照射的患者为0.00032,接受照射的患者为0.00055)。EBRT可能是间皮瘤的一个决定因素。潜伏期越长,风险越高,而剂量反应似乎是非线性的。EBRT用于原发性实体癌后间皮瘤的临床影响有限。